Breast cancer is the most common cancer in women, and approximately 71% of carcinomas
are hormone receptor‐positive (HR+) and human epidermal growth factor receptor 2‐not …

As a field we have made tremendous strides in treating breast cancer, with a decline in the
past 30 years of overall breast cancer mortality. However, this progress is met with little affect …

Принципы лечения HR+-HER2-метастатического рака молочной железы (мРМЖ) в
течение длительного периода времени оставались неизменными. Последовательное …

Purpose: Mutations of the PI3K/AKT/mTOR signaling pathway occur in 70% of all breast
cancers and represent a clinically useful marker for disease prognosis and patient …

PIK3CA 靶向药物也在临床上得到开发和试验验证. PI3K 抑制剂已批准用于PIK3CA 突变,
激素受体阳性且HER2 阴性(HR+/HER2−) 晚期乳腺癌患者. 然而并非所有患者都能从靶向治疗 …

目的探讨乳腺癌标本中磷脂酰肌醇激酶-3-催化亚基α (PIK3CA) 突变与侵袭性乳腺癌临床病理
特征及预后的相关性. 方法收集2018 年1 月至2020 年1 月确诊为乳腺癌的181 …

Purpose To evaluate the prognostic significance of progesterone receptor (PR) expression
and the PIK3CA mutation status in HR+/HER2− breast cancer patients, with the goal of …

Abstract" Success is the ability to move from failure to failure without losing enthusiasm," or
the lessons we have learned The principles of treatment for HR+ HER2-metastatic breast …

Objective To find the correlation between phosphatidylinositol kinase-3 catalytic subunit A
gene (PIK3CA) mutation and pathological features as well as clinical prognosis of breast …